metaEvidence - overview


			deaths (OS)
Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)
versus placebo
	nivolumab alone vs. placebo	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	nivolumab plus ipilimumab vs. placebo	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
versus etoposide plus platin
	durvalumab plus etoposide and platin vs. etoposide plus platin	1	-945 [-1760; -130] /10000 155/268 vs. 181/269
	durvalumab plus tremelimumab plus SoC vs. etoposide plus platin	1	-863 [-1516; -211] /10000 207/268 vs. 231/269
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	-1460 [-2409; -510] /10000 104/201 vs. 134/202
	ipilimumab plus SoC vs. placebo plus SoC	1	-178 [-734; 378] /10000 350/478 vs. 357/476
	pembrolizumab plus SoC vs. placebo plus SoC	1	-943 [-1690; -196] /10000 169/228 vs. 188/225